Please login to the form below
carflizomib
This page shows the latest carflizomib news and features for those working in and with pharma, biotech and healthcare.
NICE set to knock-back Amgen's myeloma treatment Kyprolis
NICE's draft guidance is part of its assessment for NHS use of Kyprolis (carflizomib) in combination with Celgene's Revlimid (lenalidomide) and dexamethasone to treat adults who have received at
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital project manager
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
-
Events Executive
-
Depending on Experience
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Assessing the value of interim analyses in clinical trials
- Patient diversity in clinical trials needs to be centre stage
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
